Back to top
more

Cardinal Health (CAH)

(Delayed Data from NYSE)

$94.16 USD

94.16
1,891,045

-0.30 (-0.32%)

Updated Jul 12, 2024 03:59 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (77 out of 250)

Industry: Medical - Dental Supplies

Better trading starts here.

Zacks News

Ecolab (ECL) Q4 Earnings & Revenues Beat, Margins Decline

Ecolab's (ECL) robust performance across all segments drives its Q4 sales despite business challenges.

PerkinElmer's (PKI) Q4 Earnings Top, Revenues Decline Y/Y

PerkinElmer's (PKI) fourth-quarter results benefit from the solid performance of the Discover & Analytics Solutions business, more than offset by lower COVID-related sales.

Charles River (CRL) Introduces Novel IgY-Based ELISA Kit

Charles River's (CRL) HCP-ELISA is built on its HCP-GAPex service, enhancing the efficiency and efficacy of HCP assay development.

ResMed's (RMD) Mask Sales Drive Growth, Margin Issue Lingers

ResMed (RMD) continues to see robust demand for its market-leading mask portfolio despite being faced with challenges related to lower new patient setups from a competitor recall.

Here's Why You Should Retain Walgreens Boots (WBA) For Now

Investors are optimistic about Walgreens Boots (WBA) on continued partnership growth and a strong focus on strategic execution.

Abbott (ABT) to Expand Vascular Device Line With New Buyout

Abbott's (ABT) latest deal will help gain access to Cardiovascular System's leading atherectomy device to treat vascular disease.

Is Cardinal Health (CAH) Stock Undervalued Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Abbott (ABT) EPD Growth Continues Amid Macroeconomic Challenges

At Abbott (ABT), Medical Device sales growth is led by strong performance in Electrophysiology, Structural Heart and Diabetes Care.

BD's (BDX) Latest Combination Test Receives the FDA's EUA

BD's (BDX) new combination test is likely to significantly aid clinicians in treating patients in the current and future respiratory virus seasons.

Cardiovascular Systems (CSII) Q2 Earnings, Revenues Miss

With the announcement of the merger agreement with Abbott, Cardiovascular Systems (CSII) refrains from providing any update on the 2023 guidance.

DexCom (DXCM) Q4 Earnings Beat Estimates, Volumes Remain Strong

DexCom's (DXCM) fourth-quarter results reflect strong domestic and international revenue growth on the back of its real-time Continuous Glucose Monitoring system.

Baxter (BAX) Q4 Earnings Miss Estimates, FY23 Outlook Weak

Baxter's (BAX) fourth-quarter results reflect impact of additional sales from the legacy Hilrom's business acquired in 2021. Ongoing macroeconomic challenges hurt earnings significantly.

3 Reasons to Retain NextGen (NXGN) Stock in Your Portfolio

NextGen's (NXGN) strong product portfolio and continued demand for its solutions raise optimism about the stock.

Haemonetics (HAE) Q3 Earnings Beat Estimates, Margins Down

In the fiscal third quarter, Haemonetics (HAE) incurs higher research and development costs, primarily due to increased investments in product innovation.

CVS Health (CVS) Q4 Earnings Surpass Estimates, Margins Down

CVS Health's (CVS) Retail/LTC segment revenues rise on increased prescription and front store volume, pharmacy drug mix and brand inflation.

Inspire Medical (INSP) Q4 Earnings, Revenues Top Estimates

Inspire Medical's (INSP) both geographic regions witness strong revenue growth in the fourth quarter.

Derek Lewis headshot

This Portfolio of 3 Dividend Aristocrats Pays Monthly

By targeting companies that pay out dividends in different months, investors can construct a portfolio that allows them to reap monthly income. Who doesn't love payday?

Here is Why Growth Investors Should Buy Cardinal (CAH) Now

Cardinal (CAH) possesses solid growth attributes, which could help it handily outperform the market.

Catalent (CTLT) Q2 Earnings Lag Estimates, Revenues Top

Catalent (CTLT) records lower revenues in both segments in its second-quarter fiscal 2023, resulting in overall soft performance.

Surmodics (SRDX) Q1 Earnings Top Estimates, FY23 View Revised

Surmodics (SRDX) reports a solid fiscal first quarter top line on the back of robust Medical Device revenues.

Is SPDR Portfolio S&P 500 High Dividend ETF (SPYD) a Strong ETF Right Now?

Smart Beta ETF report for SPYD

LabCorp's (LH) New Launches, Planned Spinoff to Aid Growth

In terms of portfolio enhancement, LabCorp (LH) enters into a collaboration with Becton, Dickinson and Company to advance in life-changing treatments for cancer and other diseases.

Avantor (AVTR) Q4 Earnings Surpass Estimates, Margins Up

Despite Avantor's (AVTR) robust core organic sales across its segments, it reports an overall soft Q4 performance.

Cardinal Health, Inc. (CAH) Is a Trending Stock: Facts to Know Before Betting on It

Zacks.com users have recently been watching Cardinal (CAH) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Zacks Industry Outlook Highlights McKesson, AmerisourceBergen, LabCorp, Cardinal Health and Merit Medical

McKesson, AmerisourceBergen, LabCorp, Cardinal Health and Merit Medical have been highlighted in this Industry Outlook article.